摘要
目的：分析氨磺必利与利培酮治疗首发精神分裂症的疗效差异。方法选择74例首发精神分裂症患者为研究对象，分别给予氨磺必利及利培酮治疗，比较BPRS量表评分、不良反应发生率。结果观察组与对照组BPRS量表评分值均明显降低，组间比较无明显差异（P＞0．05）；观察组不良反应发生率（18．92％）明显低于对照组（P＜0．05）。结论氨磺必利与利培酮均可有效治疗首发精神分裂症，氨磺必利不良反应较少，具有优良的治疗安全性。
Abstract
Objective To analysis efficacy of amisulpride and risperidone treatment first -episode schizophrenia.Methods 74 patients with first -episode schizo-phrenia were given Amisulpride and risperidone therapy,BPRS score,adverse reaction were compared.Result BPRS rating scale values were significantly reduced,be-tween groups was no significant difference;observation group adverse reactions(18.92%) was obviously lower than the control group.Conclusion Amisulpride and risper-idone can be effective in the treatment of first-episode schizophrenia,Amisulpride low adverse reaction,good safety.
NETL
NSTL
万方数据